Loading...
Loading...
Clover Biopharmaceuticals, Ltd.
Clover Biopharmaceuticals, Ltd.. Spoken Alpha tracks CBPHF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks CBPHF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CBPHF.
curl https://api.spokenalpha.com/v1/companies/CBPHF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.94 | $3.77 | -22.0% | +8.5% | +9.9% |
| Q4 FY2026 | $3.01 | $3.99 | -24.6% | +3.6% | +1.9% |
| Q3 FY2026 | $3.49 | $4.05 | -13.8% | +1.8% | +3.3% |
| Q2 FY2026 | $3.44 | $3.94 | -12.7% | +4.0% | +6.0% |
| Q1 FY2025 | $3.02 | $3.85 | -21.5% | +3.6% | +2.7% |
| Q4 FY2025 | $3.14 | $4.01 | -21.7% | +4.6% | +6.6% |
| Q3 FY2025 | $3.02 | $3.95 | -23.5% | +0.4% | +0.5% |
| Q2 FY2025 | $3.07 | $4.11 | -25.2% | -1.8% | 0.0% |
| Q1 FY2024 | $3.69 | $4.16 | -11.2% | +9.0% | +11.2% |
| Q4 FY2024 | $3.37 | $4.18 | -19.4% | +5.0% | +7.0% |